Sectoral Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Sectoral Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-178,000	Closed	-$1.09M	–	74
2019 Q4	$1.09M	Sell	178,000 -18,000	-9%	-$74.1K	0.16%	61
2019 Q3	$817K	Buy	196,000 +20,000	+11%	+$159K	0.14%	62
2019 Q2	$2.31M	Buy	+176,000	New	+$2.16M	0.28%	62

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sectoral Asset Management's PHAS Position: Q1 2020 in Review

Sectoral Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2020, closing a stake of 178,000 shares — an estimated $1.09M sold.

Sectoral Asset Management first reported a position in PHAS in Q2 2019 and held it in 3 quarters. The position peaked at $2.31M in Q2 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q1 2020.

Sectoral Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Sectoral Asset Management sold 178,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $1.09M.
Sectoral Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
Sectoral Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.31M in Q2 2019.
50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Sectoral Asset Management's 13F filing for Q1 2020, filed 13 May 2020.